GlassScriptPhysician profile
Lisette Peralta
NPI 1568770725
$5,387.85
in general payments reported to CMS, 2019-2025
18 companies · $2,780 in 2025
The $2,780 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $157 · 2022: $12.83 · 2023: $447 · 2024: $1,991 · 2025: $2,780.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,892 · Consulting Fee: $1,920 · Education: $406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,891.65 |
| Consulting Fee | $1,920.00 |
| Education | $405.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $1,617.64 | 2023-2025 | Dupixent |
| Arcutis Biotherapeutics, INC. | $1,032.26 | 2024-2025 | Zoryve |
| Galderma Laboratories, L.P. | $412.06 | 2021-2025 | Nemluvio, Aklief |
| Janssen Biotech, INC. | $342.79 | 2023-2025 | Tremfya, Stelara, Simponi |
| Incyte Corporation | $312.49 | 2023-2025 | Opzelura |
| Abbvie INC. | $311.60 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $270.43 | 2024 | Sotyktu |
| Leo Pharma INC. | $264.11 | 2025 | Anzupgo, Adbry |
| Genzyme Corporation | $208.66 | 2022-2024 | |
| Pfizer INC. | $133.68 | 2021-2025 | |
| Dermavant Sciences, INC. | $131.94 | 2023-2024 | Vtama |
| Ucb, INC. | $89.69 | 2024 | Bimzelx |
| Sanofi-Aventis U.S. LLC | $85.00 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $56.40 | 2023 | Dupixent |
| Vyne Pharmaceuticals INC. | $53.00 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $44.03 | 2021-2025 | Otezla |
| Lilly USA, LLC | $15.96 | 2024 | Olumiant |
| Organon LLC | $6.11 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisette Peralta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.